Download PDF
Drug Res (Stuttg) 2014; 64(12): 695-696
DOI: 10.1055/s-0034-1368727
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Should Warfarin and Heparins be Replaced by the New Oral Anticoagulants?

M. S. Farooq
1   Medical Student at Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
,
M. Z. Farooq
1   Medical Student at Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
,
S. Khan
1   Medical Student at Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
› Author Affiliations
Further Information

Publication History

received 01 December 2013

accepted 04 February 2014

Publication Date:
05 March 2014 (online)

Also available at
    Permissions and Reprints

Abstract

The results of phase 3 clinical trials of the new oral anticoagulants portray them as a promising new class of drugs with potential to replace the conventional anticoagulants. However, the transition from conventional to new oral anticoagulants will be gradual because of the deep seated roots of the conventional drugs in clinical practice and the high cost of the new agents.

 

  • References

  • 1 Wanat M A. “Novel oral anticoagulants: A review of new agents”. Postgraduate medicine 125: 103-114
    PubMedGoogle Scholar
  • 2 Hirsh J. “Current anticoagulant therapy – unmet clinical needs”. Thrombosis Research 2003; 109: S1-S8
    CrossrefPubMedGoogle Scholar
  • 3 Weitz J, Gross P. New oral anticoagulants: which one should my patient use?. ASH Education Program Book 2012 2012: 536-540
    PubMedGoogle Scholar
  • 4 Tahir F, Riaz H, Riaz T et al. The new oral anti-coagulants and the phase 3 clinical trials – a systematic review of the literature. Thrombosis journal 2013; 11: 1-8
    CrossrefPubMedGoogle Scholar
  • 5 Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2013 doi: 10.1016/S0140-6736(13)62343-0
    PubMedGoogle Scholar
  • 6 Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective anticoagulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48). Am Heart J 2010; 160: 635-641
    CrossrefPubMedGoogle Scholar